Semaglutide study for brain blood flow in type 2 diabetes
Part of Brain & nervous system, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests whether semaglutide changes blood flow in the brain and the brain’s “barrier” (how well the brain is protected) in people with type 2 diabetes. It may help researchers understand brain-related effects of diabetes treatment using scans and blood tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 65 years old
- You have type 2 diabetes for at least 3 years, and your recent A1C is 7% to 10%
- Your diabetes is being managed with one or more approved medicines (like insulin, metformin, sulfonylureas, or SGLT2 inhibitors)
- You can get an MRI (and any needed contrast dye) and you can safely do home glucose checks
- Your kidney function is not too low (eGFR must be 45 or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether semaglutide (a diabetes drug) can help protect kidney function in people with type 2 diabetes who already have mild to moderate kidney damage. You will take semaglutide or a placebo and have regular kidney function tests.
This study tests if a weekly injection (semaglutide) combined with an exercise program can help reduce fat stored in the heart and muscles in people with type 2 diabetes. It may improve how well your body handles sugar and lowers your risk for heart problems.
This study uses MRI scans to look at how the diabetes medication semaglutide affects body composition in people with type 2 diabetes and obesity. It may help doctors understand how this treatment works in the body.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This study tests whether the diabetes medication semaglutide can reduce inflammation and improve blood vessel health in people with type 2 diabetes who have no significant heart artery blockages. If you have diabetes and are at moderate to high heart risk but haven't had heart problems, this could help understand the medicine's extra benefits beyond blood sugar control.
This Phase 2 study tests whether a semaglutide injection given under the skin soon after an acute ischemic stroke can improve recovery. It may help reduce disability, especially if treatment starts within about 4.5 hours of symptom onset.
Hear when a new Stroke (CVA) or Transient Ischemic Attack trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.